biostudies-literaturePiotrowski AFNCI NIH HHSBeOne Medicines Ltd.NIH HHS541https://www.ebi.ac.uk/biostudies/studies/S-EPMC12562933biostudies-literatureUnknown32(10)Pamiparib, a small-molecule poly (ADP-ribose) polymerase (PARP) 1/2 inhibitor, demonstrates strong PARP-DNA complex trapping, antitumor activity, and blood-brain barrier penetration. This phase Ib/II dose-escalation study (NCT03150862) investigated pamiparib's tolerability/safety and efficacy when combined with radiotherapy and/or low-dose temozolomide (TMZ) in patients with treatment-naïve (Arms A and B) and recurrent/refractory (Arm C) glioblastoma. The recommended phase II dose for Arm A was pamiparib 60 mg twice daily (BID) for 6 weeks with 6-7 weeks radiotherapy; the recommended dose for Arm C was pamiparib 60 mg BID plus 60 mg TMZ (days 1-7; 28-day cycle). The Arm B escalation cohort completed enrollment; the expansion cohort was not opened. Grade ≥3 treatment-emergent adverse eventsCurrent oncology (Toronto, Ont.)Phase Ib/II Study of Pamiparib Plus Radiation Therapy and/or Temozolomide in Adult Patients with Treatment-Naive or Recurrent/Refractory Glioblastoma.PMC1256293301P30CA008748-24P30 CA008748Gisin VPiotrowski AFShih KBadruddoja MCloughesy TZhu ZGiglio PColman HCampian JLWen PYButowski NfalsePhase Ib/II Study of Pamiparib Plus Radiation Therapy and/or Temozolomide in Adult Patients with Treatment-Naive or Recurrent/Refractory Glioblastoma.Pamiparib, a small-molecule poly (ADP-ribose) polymerase (PARP) 1/2 inhibitor, demonstrates strong PARP-DNA complex trapping, antitumor activity, and blood-brain barrier penetration. This phase Ib/II dose-escalation study (NCT03150862) investigated pamiparib's tolerability/safety and efficacy when combined with radiotherapy and/or low-dose temozolomide (TMZ) in patients with treatment-naïve (Arms A and B) and recurrent/refractory (Arm C) glioblastoma. The recommended phase II dose for Arm A was pamiparib 60 mg twice daily (BID) for 6 weeks with 6-7 weeks radiotherapy; the recommended dose for Arm C was pamiparib 60 mg BID plus 60 mg TMZ (days 1-7; 28-day cycle). The Arm B escalation cohort completed enrollment; the expansion cohort was not opened. Grade ≥3 treatment-emergent adverse events2025-01-01T00:00:00Z2025 Sep2026-05-15T03:18:27.181Z2026-05-15T03:12:26.29ZS-EPMC125629334114946110.3390/curroncol32100541